Akshara Srivastava, Sanket Koul

Stories by Akshara Srivastava, Sanket Koul

US Business Schools Eye India Partnerships

US Business Schools Eye India Partnerships

Rediff.com   1 days ago

The outreach comes amid a drop in Indian student enrolments in management programmes at American universities last year, following changes to US student visa policies.

Obesity Drug Can't Be Advertised Anymore

Obesity Drug Can't Be Advertised Anymore

Rediff.com   1 days ago

'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'

India Targets 200,000 Foreign Students by 2030

India Targets 200,000 Foreign Students by 2030

Rediff.com   2 days ago

The government has intensified its Study in India programme and is working closely with universities and states to achieve this goal.

'We Wanted To Create A Brand From India For The World'

'We Wanted To Create A Brand From India For The World'

Rediff.com   2 Mar 2026

"There is an India that is embracing global luxury symbols and another which, as it evolves, is comfortable owning its 'Indian-ness'. We're deeply rooted in India, yet global," say Nicobar Design founders Simran Lal and Raul Rai.

Abbott Bets On Semaglutide Boom

Abbott Bets On Semaglutide Boom

Rediff.com   28 Feb 2026

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.

CDSCO allows immediate lab testing of drugs to speed up approvals

CDSCO allows immediate lab testing of drugs to speed up approvals

Rediff.com   27 Feb 2026

The Centre has allowed companies to begin lab testing immediately after filing applications instead of waiting for detailed scrutiny, in a move to expedite approvals for manufacture, or import of new drugs.

Gurugram Dethrones Mumbai As India's Luxury Housing Capital

Gurugram Dethrones Mumbai As India's Luxury Housing Capital

Rediff.com   24 Feb 2026

Gurugram has overtaken Mumbai to become India's biggest luxury housing market in 2025, recording 24,120 crore in sales of homes priced above 10 crore.

Empty PG Seats, Missing Doctors

Empty PG Seats, Missing Doctors

Rediff.com   23 Feb 2026

'When young doctors see limited protection, unpredictable careers and an absence of institutional support, they hesitate.'

Indian pharma to get stronger dose of EU mkt access

Indian pharma to get stronger dose of EU mkt access

Rediff.com   5 Feb 2026

The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.

Realty to get indirect push from Budget proposals

Realty to get indirect push from Budget proposals

Rediff.com   3 Feb 2026

The government's Budget announcements providing tax holiday for data centres, setting up of city economic regions (CERs) and funding to improve infrastructure in Tier-II and -III cities may give an indirect boost to India's realty sector, said industry executives.

Indra Nooyi's Career Advice For Women

Indra Nooyi's Career Advice For Women

Rediff.com   29 Jan 2026

'Women must prioritise financial security.'

Indian Travel Gets Personal in 2026

Indian Travel Gets Personal in 2026

Rediff.com   28 Jan 2026

Ultra-personalisation is the new standard for Indian tourists.

Centre mandates blue strip on antimicrobial drugs to curb overuse

Centre mandates blue strip on antimicrobial drugs to curb overuse

Rediff.com   24 Jan 2026

The Union health ministry has issued draft rules to mandate a blue vertical strip on all antimicrobial drug labels, aiming to rein in over-the-counter misuse and tackle India's growing antimicrobial resistance (AMR) problem.

Dr Reddy's profit down 14% on low Lenalidomide US sales

Dr Reddy's profit down 14% on low Lenalidomide US sales

Rediff.com   22 Jan 2026

Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.

NEET-PG Cutoff Cut Sparks Merit Debate

NEET-PG Cutoff Cut Sparks Merit Debate

Rediff.com   22 Jan 2026

'To fill these seats, eligibility is being diluted. We are compromising merit and producing degree holders instead of good doctors.'

Alcoholic Beverages players identify new markets amid tax hiccups

Alcoholic Beverages players identify new markets amid tax hiccups

Rediff.com   21 Jan 2026

Makers of spirits, beer, and wine are working to identify new markets of growth as two of the industry's biggest liquor markets, Maharashtra and Telangana, remain embroiled in taxation and payment issues.

Govt Bans Sale Of Oral Nimesulide

Govt Bans Sale Of Oral Nimesulide

Rediff.com   2 Jan 2026

The Union health ministry has banned the manufacture, sale and distribution of all oral formulations containing the popular painkiller nimesulide above 100 milligrams for human use, citing health risks.

Centre Proposes Stricter Cough Syrup Rules

Centre Proposes Stricter Cough Syrup Rules

Rediff.com   1 Jan 2026

Following the death of 22 children due to consumption of contaminated cough syrups in Madhya Pradesh three months ago, the Union health ministry has proposed amendments in the country's drug rules to ensure a tougher criterion for their over-the-counter (OTC) sales in India.

Why non- NCR developers are flocking to Gurugram

Why non- NCR developers are flocking to Gurugram

Rediff.com   30 Dec 2025

Gurugram, already established as the corporate hub of Delhi-NCR, is increasingly attracting developers from outside the region, drawn by robust end-user demand, premium pricing, and emerging development opportunities.

Weightloss Drugs Hit 1,000 Crore Mark

Weightloss Drugs Hit 1,000 Crore Mark

Rediff.com   22 Dec 2025

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'